lncRNA ZEB2‑AS1 stimulates cardiac hypertrophy by downregulating PTEN

Cheng,Zhi; Liu,Lingyun; Li,Qingguo

doi:10.3892/etm.2020.9220

lncRNA ZEB2‑AS1 stimulates cardiac hypertrophy by downregulating PTEN

Authors:
- Zhi Cheng
- Lingyun Liu
- Qingguo Li
View Affiliations

Affiliations: Cardiovascular Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210003, P.R. China
Published online on: September 16, 2020 https://doi.org/10.3892/etm.2020.9220
Article Number: 92

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cardiac hypertrophy (CH) is closely related to a range of cardiovascular diseases, including heart failure and sudden cardiac death. The present study aimed to elucidate the role of long non‑coding RNA (lncRNA) ZEB2 antisense RNA 1 (ZEB2‑AS1) in regulating the hypertrophic process of cardiomyocytes and the potential underlying mechanism. An in vivo CH mouse model was established by performing transverse aortic constriction procedures. An in vitro CH model was established in primary cardiomyocytes isolated from mice by phenylephrine (PE) treatment. The relative protein levels of BNP, ANP and PTEN in cells with different groups (CH group and control group) were determined by western blotting. Relative expression levels of ZEB2‑AS1, natriuretic peptide A (ANP) and brain natriuretic peptide (BNP) were determined in both in vivo and in vitro CH models. The regulatory effects of ZEB2‑AS1/phosphatase and tensin homolog (PTEN) on cell surface area, and the relative expression levels of ANP and BNP were explored. ZEB2‑AS1, ANP and BNP expression levels were increased in both in vivo and in vitro CH models compared with the sham and negative control groups, respectively. ZEB2‑AS1 knockdown decreased cell surface area, and downregulated ANP and BNP expression levels in PE‑treated primary cardiomyocytes. Similarly, PTEN overexpression reduced cell surface area, and downregulated ANP and BNP expression levels in PE‑treated primary cardiomyocytes. Moreover, PTEN reversed the regulatory effects of ZEB2‑AS1 on hypertrophic cardiomyocytes. Therefore, the present study suggested that lncRNA ZEB2‑AS1 may influence the progression of CH by downregulating PTEN.

View Figures

View References

1	Li X, Lan Y, Wang Y, Nie M, Lu Y and Zhao E: Telmisartan suppresses cardiac hypertrophy by inhibiting cardiomyocyte apoptosis via the NFAT/ANP/BNP signaling pathway. Mol Med Rep. 15:2574–2582. 2017.PubMed/NCBI View Article : Google Scholar
2	Facundo H, Brainard RE, Caldas F and Lucas A: Mitochondria and cardiac hypertrophy. Adv Exp Med Biol. 982:203–226. 2017.PubMed/NCBI View Article : Google Scholar
3	Tham YK, Bernardo BC, Ooi JY, Weeks KL and McMullen JR: Pathophysiology of cardiac hypertrophy and heart failure: Signaling pathways and novel therapeutic targets. Arch Toxicol. 89:1401–1438. 2015.PubMed/NCBI View Article : Google Scholar
4	Haque ZK and Wang DZ: How cardiomyocytes sense pathophysiological stresses for cardiac remodeling. Cell Mol Life Sci. 74:983–1000. 2017.PubMed/NCBI View Article : Google Scholar
5	Shen S, Jiang H, Bei Y, Xiao J and Li X: Long non-coding RNAs in cardiac remodeling. Cell Physiol Biochem. 41:1830–1837. 2017.PubMed/NCBI View Article : Google Scholar
6	Viereck J, Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M, Dittrich M, Maetzig T, Zimmer K, et al: Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med. 8(326ra22)2016.PubMed/NCBI View Article : Google Scholar
7	Zhou G, Li C, Feng J, Zhang J and Fang Y: lncRNA UCA1 is a novel regulator in cardiomyocyte hypertrophy through targeting the miR-184/HOXA9 axis. Cardiorenal Med. 8:130–139. 2018.PubMed/NCBI View Article : Google Scholar
8	Shao M, Chen G, Lv F, Liu Y, Tian H, Tao R, Jiang R, Zhang W and Zhuo C: lncRNA TINCR attenuates cardiac hypertrophy by epigenetically silencing CaMKII. Oncotarget. 8:47565–47573. 2017.PubMed/NCBI View Article : Google Scholar
9	Zhu XH, Yuan YX, Rao SL and Wang P: lncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. Eur Rev Med Pharmacol Sci. 20:3653–3660. 2016.PubMed/NCBI
10	Wo Y, Guo J, Li P, Yang H and Wo J: Long non-coding RNA CHRF facilitates cardiac hypertrophy through regulating Akt3 via miR-93. Cardiovasc Pathol. 35:29–36. 2018.PubMed/NCBI View Article : Google Scholar
11	Huarte M: The emerging role of lncRNAs in cancer. Nat Med. 21:1253–1261. 2015.PubMed/NCBI View Article : Google Scholar
12	Wu X, Yan T, Wang Z, Wu X, Cao G and Zhang C: lncRNA ZEB2-AS1 promotes bladder cancer cell proliferation and inhibits apoptosis by regulating miR-27b. Biomed Pharmacother. 96:299–304. 2017.PubMed/NCBI View Article : Google Scholar
13	Gao H, Gong N, Ma Z, Miao X, Chen J, Cao Y and Zhang G: lncRNA ZEB2-AS1 promotes pancreatic cancer cell growth and invasion through regulating the miR-204/HMGB1 axis. Int J Biol Macromol. 116:545–551. 2018.PubMed/NCBI View Article : Google Scholar
14	Wang F, Zhu W, Yang R, Xie W and Wang D: lncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer via activating the Wnt/β-catenin pathway. Mol Cell Biochem. 451:73–83. 2019.PubMed/NCBI View Article : Google Scholar
15	Wang K, Lin ZQ, Long B, Li JH, Zhou J and Li PF: Cardiac hypertrophy is positively regulated by MicroRNA miR-23a. J Biol Chem. 287:589–599. 2012.PubMed/NCBI View Article : Google Scholar
16	Forlenza M, Kaiser T, Savelkoul HF and Wiegertjes GF: The use of real-time quantitative PCR for the analysis of cytokine mRNA levels. Methods Mol Biol. 820:7–23. 2012.PubMed/NCBI View Article : Google Scholar
17	Creemers EE, Wilde AA and Pinto YM: Heart failure: Advances through genomics. Nat Rev Genet. 12:357–362. 2011.PubMed/NCBI View Article : Google Scholar
18	Frey N and Olson EN: Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol. 65:45–79. 2003.PubMed/NCBI View Article : Google Scholar
19	Braunwald E: The war against heart failure: The Lancet lecture. Lancet. 385:812–824. 2015.PubMed/NCBI View Article : Google Scholar
20	Huang Q and Cai B: Exosomes as new intercellular mediators in development and therapeutics of cardiomyocyte hypertrophy. Adv Exp Med Biol. 998:91–100. 2017.PubMed/NCBI View Article : Google Scholar
21	McMullen JR and Jennings GL: Differences between pathological and physiological cardiac hypertrophy: Novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol. 34:255–262. 2007.PubMed/NCBI View Article : Google Scholar
22	Bernardo BC, Weeks KL, Pretorius L and McMullen JR: Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol Ther. 128:191–227. 2010.PubMed/NCBI View Article : Google Scholar
23	van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA and Olson EN: A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA. 103:18255–18260. 2006.PubMed/NCBI View Article : Google Scholar
24	Bao Q, Zhao M, Chen L, Wang Y, Wu S, Wu W and Liu X: MicroRNA-297 promotes cardiomyocyte hypertrophy via targeting sigma-1 receptor. Life Sci. 175:1–10. 2017.PubMed/NCBI View Article : Google Scholar
25	Malaney P, Uversky VN and Dave V: PTEN proteoforms in biology and disease. Cell Mol Life Sci. 74:2783–2794. 2017.PubMed/NCBI View Article : Google Scholar
26	Wise HM, Hermida MA and Leslie NR: Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond). 131:197–210. 2017.PubMed/NCBI View Article : Google Scholar
27	Zhang HM, Fan TT, Li W and Li XX: Expressions and significances of TTF-1 and PTEN in early endometrial cancer. Eur Rev Med Pharmacol Sci. 21:20–26. 2017.PubMed/NCBI
28	Zhang R, Guo Y, Ma Z, Ma G, Xue Q, Li F and Liu L: Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer. Oncotarget. 8:26079–26089. 2017.PubMed/NCBI View Article : Google Scholar
29	Shen W, Li HL, Liu L and Cheng JX: Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer. Eur Rev Med Pharmacol Sci. 21:2596–2603. 2017.PubMed/NCBI
30	Ngeow J, Sesock K and Eng C: Breast cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Res Treat. 165:1–8. 2017.PubMed/NCBI View Article : Google Scholar
31	Sun J, Li T, Zhao Y, Huang L, Sun H, Wu H and Jiang X: USP10 inhibits lung cancer cell growth and invasion by upregulating PTEN. Mol Cell Biochem. 441:1–7. 2018.PubMed/NCBI View Article : Google Scholar
32	Li MF, Guan H and Zhang DD: Effect of overexpression of PTEN on apoptosis of liver cancer cells. Genet Mol Res 15, 2016.
33	Beg S, Siraj AK, Jehan Z, Prabakaran S, Al-Sobhi SS, Al-Dawish M, Al-Dayel F and Al-Kuraya KS: PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma. Br J Cancer. 112:1938–1943. 2015.PubMed/NCBI View Article : Google Scholar
34	Guo C, Song WQ, Sun P, Jin L and Dai HY: lncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells. J Biomed Sci. 22(100)2015.PubMed/NCBI View Article : Google Scholar
35	Wang J, Xu W, He Y, Xia Q and Liu S: lncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN. Inflamm Res. 67:927–936. 2018.PubMed/NCBI View Article : Google Scholar
36	Qiao Q and Li H: lncRNA FER1L4 suppresses cancer cell proliferation and cycle by regulating PTEN expression in endometrial carcinoma. Biochem Biophys Res Commun. 478:507–512. 2016.PubMed/NCBI View Article : Google Scholar